Literature DB >> 9398818

Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.

N Rieger1, J Stahl, D Wattchow.   

Abstract

A case is reported where intractable Crohn's disease responded to chemotherapy for breast carcinoma. The drug most likely responsible was cyclophosphamide. Cyclophosphamide may have a role in the management of inflammatory bowel disease, but this needs to be confirmed before it can be recommended as a treatment option.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9398818     DOI： 10.1023/a:1018843507275

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  11 in total

Review 1.  Medical management of severe inflammatory disease of the rectum and distal colon: non-nutritional aspects.

Authors:  R J Polson; J J Misiewicz
Journal:  Baillieres Clin Gastroenterol       Date:  1992-03

2.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J M Willoughby; J Beckett; P J Kumar; A M Dawson
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

3.  Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.

Authors:  P A Van Hees; H J Van Lier; P H Van Elteren; M Driessen; R A Van Hogezand; G P Ten Velde; J H Bakker; J H Van Tongeren
Journal:  Gut       Date:  1981-05       Impact factor: 23.059

4.  A controlled trial of azathioprine in Crohn's disease.

Authors:  J L Rosenberg; B Levin; A J Wall; J B Kirsner
Journal:  Am J Dig Dis       Date:  1975-08

5.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

Review 6.  Clinical use of immunosuppressive drugs: part I.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

7.  Metronidazole in Crohn's disease. A double blind cross-over clinical trial.

Authors:  P Blichfeldt; J P Blomhoff; E Myhre; E Gjone
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

8.  Clinical use of immunosuppressive drugs: part II.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 9.  Cutaneous polyarteritis nodosa associated with Crohn's disease. Report and review of the literature.

Authors:  B Gudbjörnsson; R Hällgren
Journal:  J Rheumatol       Date:  1990-03       Impact factor: 4.666

10.  Effect of the immune modulating agents cyclophosphamide, methotrexate, hydrocortisone, and cyclosporin A on an animal model of granulomatous bowel disease.

Authors:  I C Mitchell; J L Turk
Journal:  Gut       Date:  1990-06       Impact factor: 23.059
View more
  1 in total

1.  Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.

Authors:  A Stallmach; B M Wittig; C Moser; J Fischinger; R Duchmann; M Zeitz
Journal:  Gut       Date:  2003-03       Impact factor: 23.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.